AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 211 min read$AEON

LYNCH TIMOTHY P purchased $243K of AEON

LYNCH TIMOTHY P purchased 1,150,000 shares of AEON Biopharma, Inc. (AEON) at $0.21 ($0.24M total) on 2026-08-19.

Original reporting
SEC EDGAR · LYNCH TIMOTHY P
Published Aug 21, 2026, 11:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 22, 2026, 12:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AEON
Bullish
medium confidence
Mentioned
$AEON
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AEONBullishLow
01

Why it matters

The filing provides fresh data on insider sentiment but limited market impact.

02

Market read

Small insider purchase; may slightly influence short‑term trading but unlikely to move the stock significantly.

03

What to watch

Potential upcoming clinical trial data could be the real driver, not the insider trade.

Relevance 5/10Novelty 3/10Timing: post-filing

Background

AEON Biopharma filed a Form 4 reporting a $243K insider purchase.

Company-level read

Ticker impact

$AEONBullishMedium confidence
Context

Form 4 filing shows insider L. Timothy purchased 1,150,000 shares at $0.2117, increasing holdings to 6.5M.

Expected impact

Potential short‑term price uptick of 1‑2% if market perceives confidence.

Evidence & confidence

Purchase size is modest relative to market cap; impact limited but could attract attention.

Market effects

Sector

Minimal effect on biotech sector; insider activity is routine.

Regional

None

Global

Low

Counterpoint

What could challenge this read

Insider purchase may be a routine portfolio rebalancing, not a bullish signal.

Key entities

  • Company
    AEON Biopharma, Inc.

    Biopharma company developing therapies.

  • Insider
    L. Timothy Lynch

    10% owner who purchased shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AEON insider trading history →

Related articles

SEP 30
$AEONHighAI 8/10

Aeon Biopharma Jumps 19% on FDA Feedback

Aeon Biopharma's shares rose 19% after the FDA agreed with its study design for ABP-450, a Botox biosimilar. The company plans to submit an investigational new drug application in Q4, with a market cap of $15 million (NYSE: AEON).

ocbj.com1 min
SEP 30
$AEONMed

AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450

AEON Biopharma received FDA feedback on its biosimilar ABP-450, clarifying the development path. The FDA agreed to consider previous studies as supportive evidence and recommended a pharmacodynamic study. AEON plans to submit an IND for this study in Q4 2026 and aims to streamline development, potentially avoiding a full clinical efficacy study. The company expects to return to the FDA in 2027 with its evidence package.

globenewswire.com2 min
SEP 9
$AEONMedAI 8/10

Aeon Claims Drug Holds Up Against Botox in Stress Test

Aeon Biopharma reported positive results from a stress test comparing its ABP-450 treatment to Botox, showing similar degradation under thermal and oxidative stress. The company plans a multi-lot comparability study. Shares of Aeon were up 1% to 23 cents, with a market cap of $11.8 million.

ocbj.com2 min
AUG 12
$AEONMedAI 8/10

AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

AEON Biopharma, Inc. (AEON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advanceme

SEC EDGAR 8-K6 min
AUG 9
$AEONMed

AEON shifts focus to Vietnam after exiting Thai supermarket business

Central Retail said its unit Central Food Retail will acquire all AEON (Thailand) ordinary shares, after signing an agreement filed Aug. 7. Completion is expected Sept. 30. MaxValu stores will be rebranded as Tops and integrated. AEON exits Thai supermarkets after 40+ years, while prioritizing Vietnam, where AEON Mall reported FY2024 revenue of about 17.3bn yen (+14%).

news.tuoitre.vn5 min